Quarterly Activities/Appendix 4C Cash Flow Report
| Stock | Control Bionics Ltd (CBL.ASX) |
|---|---|
| Release Time | 31 Jul 2026, 8:31 a.m. |
| Price Sensitive | Yes |
Control Bionics Reports Quarterly Activities for June 2026
- Completed Tranche 1 of A$9.8M capital raising
- Professor Nicholas Opie joins Board as strategic advisor
- US wholesale revenue momentum building
- NextLevel iOS device program on track for Q1FY27
- NeuroStrip commercial activity expanding
Control Bionics Limited announced its Quarterly Activities Report and Appendix 4C for the quarter ended 30 June 2026. Key highlights include the completion of Tranche 1 of its A$9.8 million capital raising, the addition of Professor Nicholas Opie to the Board, and increasing US wholesale revenue. The NextLevel iOS device program is on track for a Q1FY27 launch, and NeuroStrip commercial activity is expanding across sports performance, rehabilitation, and research settings. The company also entered into a $400,000 loan facility secured against its anticipated FY26 R&D tax incentive refund. Despite challenges such as NDIS approval delays in Australia and a slower-than-expected transition from retail to wholesale in North America, the company remains focused on disciplined execution and progressing towards key strategic milestones.
Completion of Tranche 2 of capital raise expected in August 2026
The company expects the NDIS environment to remain challenging in the near term and the North American transition to continue over coming quarters.